The Role of Chemotherapy in Anaplastic Astrocytoma Patients
Journal of Korean Neurosurgical Society
; : 199-202, 2012.
Article
in En
| WPRIM
| ID: wpr-143953
Responsible library:
WPRO
ABSTRACT
OBJECTIVE:
This retrospective study was performed to evaluate the role of chemotherapy in the management of patients with anaplastic astrocytoma (AA).METHODS:
We compared the survival outcome among the 3 different treatment protocol groups in a single institution. A total of 86 patients (39 men and 47 women) with newly diagnosed AA after surgery were analyzed. Among them, 31 patients (36.0%) were treated with radiotherapy only (RT Group), 30 patients (34.9%) were treated with nimustine-cisplatin chemotherapy before RT (ACNU-CDDP group), and 25 patients (29.1%) were treated with procarbazine, lomustine and vincristine (PCV) chemotherapy after radiotherapy (PCV group).RESULTS:
The median survival was 14.0, 30.0 and 72.0 months in RT, ACNU-CDDP, and PCV group, respectively and showed significant differences (RT vs. ACNU-CDDP; p=0.039, RT vs. PCV; 0.002, ACNU-CDDP vs. PCV; 0.045). PCV group showed less toxicity rate (5 patients; 20%) than ACNU-CDDP group (12 patients; 40%), while only 3 patients (9.6%) in RT group experienced grade 3 or 4 toxicities.CONCLUSION:
An application of chemotherapy before or after radiotherapy is beneficial in prolonging the survival of patients with AA. Adjuvant PCV chemotherapy after radiotherapy is recommendable.Key words
Full text:
1
Index:
WPRIM
Main subject:
Procarbazine
/
Astrocytoma
/
Vincristine
/
Clinical Protocols
/
Retrospective Studies
/
Lomustine
Type of study:
Guideline
/
Observational_studies
Limits:
Humans
/
Male
Language:
En
Journal:
Journal of Korean Neurosurgical Society
Year:
2012
Type:
Article